Brief: Iconovo Gets Positive FDA Guidance on Icopre Substitutability

Iconovo AB

20/09/2024 08:59

Sept 20 (Reuters) - Iconovo AB  ICO.ST :
    * ICONOVO RECEIVES POSITIVE GUIDANCE FROM FDA REGARDING
SUBSTITUTABILITY FOR ICOPRE®
    * NEXT STEP IN DEVELOPMENT OF GENERIC BREO/RELVAR IN ICOPRE
WILL
BE TO CONDUCT PHARMACOKINETIC STUDY
    * FINDING PARTNER COMPANY HAS TAKEN MORE TIME THAN ESTIMATED
BUT
CONTINUES WITH CONSTRUCTIVE NEGOTIATIONS
    * OUT-LICENSING PROCESS IS EXPECTED TO BE COMPLETED IN 2024

Source text for Eikon:  ID:nMFN28Cvr 
Further company coverage:  ICO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))